caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the muscarinic agonist class of molecules. | COC(=O)C1CNCCC1C(=O)O | [
"muscarinic agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts thyroxine treatment, atherosclerosis, and pancreatitis. The molecule is a nutrient and a fat storage, impacting both metabolic syndrome and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Thyroxine treatment",
"Atherosclerosis",
"Pancreatitis",
"Metabolic syndrome",
"nutrient",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging. The molecule is a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic light-emitting device and belongs to the electroluminescent device class of molecules, with the characteristic of being electroluminescent. | C1=Cc2cc(-c3ccc(C4=CC5NC(c6ccc7c(c6)NC(C6=CCNC=C6)C=C7)=CC=C5C=C4)cc3)c3c(c2NC1)NCC=C3 | [
"electroluminescent",
"organic light-emitting device",
"electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hepatitis b treatment and belongs to the anti viral class of molecules. | COCCCOc1cc(CC2(N)CCC2)ccc1Cl | [
"hepatitis B treatment",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a paf antagonist and a platelet aggregation inhibitor. | CCCOc1c(OCCCSc2ncc[nH]2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)=O | [
"paf antagonist",
"platelet aggregation inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, fat storage, energy source that impacts cardiovascular disease, metabolic syndrome, and cancer. The molecule is a membrane stabilizer and thyroxine treatment, and it impacts atherosclerosis. The molecule is a energy storage and a inflammatory, impacting both pancreatitis and obesity. | CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Fat storage",
"Energy source",
"Cancer",
"Atherosclerosis",
"Membrane stabilizer",
"Thyroxine treatment",
"Energy storage",
"inflammatory",
"Pancreatitis",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, tangier disease, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Apoptosis",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging. The molecule is a apoptosis that impacts barth syndrome, tangier disease, diabetic heart disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1ccc(/C=C/c2cc(OC)c(O)c(OC)c2)cc1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects cervical cancer by impacting atherosclerosis, ulcerative colitis, and breast cancer. | CC/C=C\C(O)C/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCc1oc(CCC)c(C)c1C)COP(=O)([O-])OCC[N+](C)(C)C | [
"Atherosclerosis",
"Cervical cancer",
"Ulcerative colitis",
"Breast cancer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. The molecule is a apoptosis and a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both thyroxine treatment and atherosclerosis. The molecule is a nutrient that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts barth syndrome, tangier disease, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC | [
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the type ii diabetes treatment class and affects metabolic syndrome treatment. | Cn1ncc(C(=O)N2CCCC3CCCC=C32)c1-c1ccc(C(C)(C)C)cc1 | [
"metabolic syndrome treatment",
"type ii diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a jak inhibitor. | COCCCCC1CCNCC1 | [
"jak inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits toxic fumes of hydrogen chloride. | O=C(O)COc1ccc(Cl)cc1 | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, barth syndrome, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Aging",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Barth syndrome",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and atherosclerosis. The molecule is a thyroxine treatment and a fat storage, impacting both pancreatitis and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCC)OC(=O)CCCCCCCCCCCCCC | [
"Cardiovascular disease",
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both pancreatitis and metabolic syndrome. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Pancreatitis",
"Thyroxine treatment",
"Metabolic syndrome",
"Cardiovascular disease",
"Fat storage",
"nutrient",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a beta-lactamase inhibitor and belongs to the anti biotic class of molecules. | O=C(O)c1cccc(CC(NS(=O)(=O)Cc2ccccc2)B(O)O)c1 | [
"beta-lactamase inhibitor",
"anti biotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCc1cnc(CC)s1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti fungal class of molecules. | O=C(O)NCCCCC(NC(=O)O)C(=O)NCCC(=O)ONC(=O)Cc1ccc(CCCCc2ccccc2)cc1 | [
"anti fungal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti oxidant class of molecules. | CCCc1cccc(CC(C(c2cccc(CCC)c2O)c2cccc(CCC)c2O)[N+](=O)[O-])c1O | [
"anti oxidant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti inflammatory class of molecules. | CC(C)c1ccc(OC(Cc2ccc(OCCNC(=O)c3ccc(OCC(F)(F)C(F)F)nc3)cc2)C(=O)[O-])cc1.[Na+] | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the electroluminescent, phosphorescent, and organic electroluminescent device classes of molecules and has an effect on electroluminescent device. | CCCCCc1ccc(-c2ccccc2)c([N+](=O)[O-])c1 | [
"electroluminescent",
"electroluminescent device",
"phosphorescent",
"organic electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts diabetic heart disease, aging, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a fibrosis treatment and a cancer treatment. | CCC(C)(C)C1(CC)CCC(=O)CC1 | [
"fibrosis treatment",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts aging, barth syndrome, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Aging",
"Apoptosis",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, energy storage, stabilizing cytochrome oxidase. The molecule is a energy source, proton trap for oxidative phosphorylation, surfactant, cholesterol translocation that impacts aging. The molecule is a nutritional supplement and smooth, impacting both bart... | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC(O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OCCCCCCCCC/C=C\CCCCCCC=O)OCCCCCCCCC/C=C\CCCCCCC=O | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Energy storage",
"Stabilizing cytochrome oxidase",
"Energy source",
"Proton trap for oxidative phosphorylation",
"surfactant",
"Cholesterol translocation",
"Aging",
"Smooth",
"Nutritional supplement",
"Barth syndrome",
"Non-alcoholic fatty... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, nutrient, emulsifier, surfactant, energy source, energy storage. | CC(C)=C1CCC(C)(O)CC1 | [
"Membrane stabilizer",
"nutrient",
"Emulsifier",
"surfactant",
"Energy source",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, nutrient, emulsifier, surfactant, membrane stabilizer, energy source. | CN1CCC23c4c5cc(-c6cc7c8c(c6O)OC6C(O)C=CC9C(C7)N(C)CCC896)c(O)c4OC2C(O)C=CC3C1C5 | [
"Energy storage",
"nutrient",
"Emulsifier",
"surfactant",
"Membrane stabilizer",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, nutrient, energy storage, creamy, and fruity. The molecule is a surfactant that is oily and waxy. The molecule is a emulsifier, clean, soapy, and green. | CC(C)=CCc1c(O)ccc2ccc(=O)oc12 | [
"creamy",
"Membrane stabilizer",
"Energy source",
"fruity",
"nutrient",
"Energy storage",
"oily",
"waxy",
"surfactant",
"clean",
"soapy",
"green",
"Emulsifier"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and metabolic syndrome. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both pancreatitis and cardiovascular disease. | CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCCCC | [
"nutrient",
"Atherosclerosis",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Pancreatitis",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC(C)=CCc1c(O)cc(O)c2c(=O)c(-c3ccc(O)cc3)coc12 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a fat storage that impacts cardiovascular disease, pancreatitis, and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a p38 map kinase inhibitor, a kinase inhibitor, and anti inflammatory. | COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(C(C)(C)C)cc(NS(C)(=O)=O)c4OC)c4ccccc34)ccn2)cc(S(=O)(=O)CCOCCOCC(=O)O)c1 | [
"p38 map kinase inhibitor",
"kinase inhibitor",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts diabetic heart disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease. The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and barth syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a liquid crystal compound and belongs to the liquid crystal class of molecules. | CCCCc1ccc(CCC2CCC(C3CCC(C4CCC(CCCCF)CC4)CC3)CC2)cc1 | [
"liquid crystal",
"liquid crystal compound"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, aging, and tangier disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ec 3.1.1.7 (acetylcholinesterase) inhibitor that is acaricide and agrochemical. | Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl | [
"acaricide",
"agrochemical",
"EC 3.1.1.7 (acetylcholinesterase) inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts cervical cancer, breast cancer, atherosclerosis, and ulcerative colitis. | CCCCCc1oc(CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)CCCCC)COP(=O)([O-])OCC[N+](C)(C)C)c(C)c1C | [
"Cervical cancer",
"Breast cancer",
"Atherosclerosis",
"nutrient",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, inflammatory, nutrient that impacts cardiovascular disease, obesity, and atherosclerosis. The molecule is a fat storage that impacts both metabolic syndrome and cancer. The molecule is a membrane stabilizer and energy storage, belonging to the thyroxine treatment class of molecules, and... | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC | [
"Energy source",
"inflammatory",
"nutrient",
"Cardiovascular disease",
"Obesity",
"Atherosclerosis",
"Fat storage",
"Metabolic syndrome",
"Cancer",
"Membrane stabilizer",
"Thyroxine treatment",
"Energy storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a fat storage that impacts pancreatitis, atherosclerosis, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts colorectal cancer, parkinson's disease, and stomach cancer. It impacts cardiovascular disease, seizure, alzheimer's disease, and diabetes mellitus. | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\C=C\C(=O)CCCCC | [
"Breast cancer",
"Colorectal cancer",
"Parkinson's disease",
"Stomach cancer",
"Cardiovascular disease",
"Seizure",
"Alzheimer's Disease",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a electrolyte. | C[NH2+]C.O=S(=O)([O-])CC(F)C(F)C(F)C(F)C(F)C(F)CCF | [
"electrolyte"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and metabolic syndrome. The molecule is a fat storage and thyroxine treatment, impacting both pancreatitis and atherosclerosis. | CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"nutrient",
"Cardiovascular disease",
"Metabolic syndrome",
"Pancreatitis",
"Fat storage",
"Thyroxine treatment",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, fat storage, energy source that impacts atherosclerosis, cancer, and pancreatitis. The molecule is a membrane stabilizer that impacts both obesity and cardiovascular disease. The molecule is a nutrient and energy storage, belonging to the thyroxine treatment class of molecules, and impac... | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC | [
"inflammatory",
"Fat storage",
"Atherosclerosis",
"Cancer",
"Pancreatitis",
"Energy source",
"Obesity",
"Membrane stabilizer",
"Cardiovascular disease",
"nutrient",
"Thyroxine treatment",
"Energy storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts aging and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC(O)CCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the liquid crystal class of molecules. | CC=CCOc1ccc(-c2ccc(C3=CCC(C)CC3)cc2)c(Cl)c1F | [
"liquid crystal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a sedative and serotonin uptake inhibitor, belonging to the anti depressant, anxiolytic drug, adrenergic antagonist, and h1-receptor antagonist classes of molecules. | Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1 | [
"anti depressant",
"sedative",
"anxiolytic drug",
"adrenergic antagonist",
"serotonin uptake inhibitor",
"H1-receptor antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is alzheimer's disease treatment. | COc1ccc2c(c1)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cccc(N3CCCC3=O)c1F)CC(C)(C)C2=O | [
"alzheimer's disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is green, cooked, fatty, and roasted. | Cc1scnc1CCOC=O | [
"green",
"cooked",
"fatty",
"roasted"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts aging. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, diabetic heart disease, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a flavoring agent and a nutrient. | CCc1nccnc1OC | [
"Flavoring agent",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts tangier disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti fungal that is both anti bacterial and anti viral. | CCOC(COCCSc1cccc(OCc2cc(C)cc(=O)n2O)c1)Sc1ccc(Cl)cc1 | [
"anti bacterial",
"anti viral",
"anti fungal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti bacterial. | CC(NCC(=O)NCC(NC(=O)c1ccc(C=Cc2ccccc2)cc1)C(=O)NO)c1ccccc1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the androgen receptor modulator class and affects both prostate cancer treatment and cancer treatment. | CC(=O)OC(CCl)COc1c(Cl)cc(S(=O)(=O)c2ccc(OCC(C)CN3CCOCC3)cc2)cc1Cl | [
"androgen receptor modulator",
"prostate cancer treatment",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti cancer agent member of the anti cancer class. | CC1CCCCC1NC(=O)c1ccc2nc(-c3ccc(NC(=O)c4ccc(F)cc4)cc3)[nH]c2c1 | [
"anti cancer",
"anti cancer agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is electroluminescent, organic light-emitting, and light-emitting. | CCc1nc2ccccc2n1-c1ccc(-c2ccc(-c3nc4ccccc4c4cc5c(cc34)C(c3ccccc3)(c3ccccc3)c3ccccc3-5)cc2)cc1 | [
"electroluminescent",
"organic light-emitting",
"light-emitting"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, food additive, energy storage that impacts non-alcoholic fatty liver disease, parkinson's disease, and alzheimer's disease. The molecule is a emulsifier, a energy source, and smooth. The molecule is a nutrient, a membrane stabilizer, and a surfactant, and it impacts diabetes me... | CCCCCc1cc(C)c(CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCc2oc(CCC)c(C)c2C)o1 | [
"Non-alcoholic fatty liver disease",
"Nutritional supplement",
"food additive",
"Energy storage",
"Parkinson's disease",
"Alzheimer's Disease",
"Emulsifier",
"Energy source",
"Smooth",
"Diabetes mellitus type 2",
"nutrient",
"Membrane stabilizer",
"surfactant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein tyrosine kinase inhibitor. | Clc1cccc(Cl)c1C#Cc1c[nH]c2ncc(-c3ccc4c(c3)CNCC4)cc12 | [
"protein tyrosine kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Cholesterol translocation",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, barth syndrome, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Chlorophenolic odor. When heated to decomposition it emits toxic fumes of hydrogen chloride. | Oc1ccc(Cl)cc1 | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, a nutritional supplement, a energy source, and smooth. The molecule is a stabilizing mitochondrial structure, energy storage, membrane stabilizer, surfactant that impacts non-alcoholic fatty liver disease. The molecule is a food additive and a cholesterol tra... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"Energy source",
"Smooth",
"Stabilizing mitochondrial structure",
"Energy storage",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"surfactant",
"food additive",
"Barth syndrome",
"Cholesterol translocation",
... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the organic light-emitting device class of molecules. | c1ccc(-n2c3ccccc3c3ccc4c5ccccc5sc4c32)c(-c2ccccc2-n2c3ccccc3c3ccc4c5ccccc5sc4c32)c1 | [
"organic light-emitting device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts neurodegenerative disease, insulin resistance, and diabetes mellitus. | CCCCC/C=C\C[C@H](O)[C@@H](O)CCCCCCCC(=O)N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCC | [
"Neurodegenerative disease",
"Insulin resistance",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and thyroxine treatment, and it impacts metabolic syndrome. The molecule is a nutrient that impacts cardiovascular disease, atherosclerosis, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCC | [
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"Pancreatitis",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory and belongs to both the anti platelet and anti malarial classes of molecules. | Nc1sc2c(c1C(=O)O)CCN(Cc1ccccc1)C2 | [
"anti inflammatory",
"anti platelet",
"anti malarial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a diabetes treatment and a type ii diabetes treatment, belonging to the inflammatory disease treatment class of molecules. | O=S(=O)(Nc1cccc(Oc2cncc(Cl)c2)c1)c1ccc(Cl)cc1Cl | [
"diabetes treatment",
"inflammatory disease treatment",
"type ii diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and cardiovascular disease. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both pancreatitis and metabolic syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCCCC | [
"Fat storage",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and aging. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and cardiovascular disease. The molecule is a thyroxine treatment and a fat storage, impacting both metabolic syndrome and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"nutrient",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Fat storage",
"Metabolic syndrome",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, membrane stabilizer, energy storage, cucumber, waxy, and green. The molecule is a nutrient, surfactant, energy source, emulsifier, violet, and leafy. | CCCCC/C=C\CO | [
"Flavoring agent",
"cucumber",
"waxy",
"Membrane stabilizer",
"Energy storage",
"green",
"nutrient",
"surfactant",
"violet",
"Energy source",
"leafy",
"Emulsifier"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a fat storage and a nutrient, it impacts atherosclerosis, and is thyroxine treatment. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)COC(=O)CCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, alzheimer's disease, and parkinson's disease. | CCCCCCCC/C=C\CCCCCC/C=C\OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"Alzheimer's Disease",
"Parkinson's disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, tangier disease, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Aging",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein tyrosine kinase inhibitor and jak inhibitor, and it impacts autoimmune disease treatment. | N#CCOc1ccc(CC(=O)N2CCN(c3ncnc4[nH]ccc34)CC3(CC3)C2)cc1 | [
"protein tyrosine kinase inhibitor",
"jak inhibitor",
"autoimmune disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment and nutrient, and it impacts atherosclerosis. The molecule is a fat storage that impacts cardiovascular disease, metabolic syndrome, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCC | [
"Thyroxine treatment",
"nutrient",
"Atherosclerosis",
"Cardiovascular disease",
"Metabolic syndrome",
"Pancreatitis",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, membrane stabilizer, fat storage, and nutrient, impacts obesity, and is thyroxine treatment. It impacts metabolic syndrome, cancer, and atherosclerosis. The molecule is a energy storage and a energy source, impacting both cardiovascular disease and pancreatitis. | CCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC | [
"inflammatory",
"Thyroxine treatment",
"Membrane stabilizer",
"Obesity",
"Fat storage",
"nutrient",
"Metabolic syndrome",
"Cancer",
"Atherosclerosis",
"Cardiovascular disease",
"Energy storage",
"Energy source",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, parkinson's disease, non-alcoholic fatty liver disease, and alzheimer's disease. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC | [
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts barth syndrome. The molecule is a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts celiac disease, inflammatory bowel disease, and diabetes mellitus type 2. The molecule is a energy source that impacts renal cell carcinoma, heart failure, and cardiovascular disease. | CCCCCCCCCCCC(C)CCCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Celiac disease",
"Inflammatory bowel disease",
"Diabetes mellitus type 2",
"Breast cancer",
"Energy source",
"Renal cell carcinoma",
"Heart failure",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pancreatitis, atherosclerosis, and cardiovascular disease. The molecule is a fat storage and a nutrient, it impacts metabolic syndrome, and is thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC(COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"Fat storage",
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and smooth, impacting both diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, nutritional supplement, apoptosis that impacts aging and barth syndrome. The molecule is a energy storage, a stabilizing mitoc... | CC(C)CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Smooth",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Cholesterol translocation",
"Barth syndrome",
"Nutritional supplement",
"Apoptosis",
"Energy storage",
"Stabilizing mitochondrial structure",
"Energy source",
"Tang... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is kinase modulator. | Nc1ncnc2c1c(-c1ccccc1)nn2C1CCCCCCC1 | [
"kinase modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a corrosion inhibitor and a anti oxidant. | CCCCC1(C)C(=O)N(CN(C2CCCC2)C2CCCC2)C(=O)N1CN(C1CCCC1)C1CCCC1 | [
"corrosion inhibitor",
"anti oxidant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.